Global Anti-Inflammatory Therapeutics Market, By Drug Class (Anti-Inflammatory Biologics, Corticosteroids, Nonsteroidal Anti-Inflammatory (NSAIDs), Others), Indications (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Anti-Inflammatory Therapeutics Market Analysis and Size
The global anti-inflammatory therapeutics market is expected to witness significant growth during the forecast period. The growth of anti-inflammatory therapeutics market is anticipated by the high prevalence of chronic disorders such as arthritis and psoriasis and rise in focuses on the anti-inflammatory therapeutics. Various government initiatives are being taken in this regard that helped in the awareness of the diseases. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global anti-inflammatory therapeutics market in the forecast period 2022-2029. The expected CAGR of global anti-inflammatory therapeutics market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 79.75 billion in 2021, and it would grow upto USD 132 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anti-inflammatory drugs are therapeutics widely used to reduce acute and mild chronic pain, which are found to be associated with chronic disorders. It is available as both over-the-counter and prescription drugs. These drugs restrict the production of certain body chemicals that cause inflammation. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Anti-Inflammatory Therapeutics Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug Class (Anti-Inflammatory Biologics, Corticosteroids, Nonsteroidal Anti-Inflammatory (NSAIDs), Others), Indications (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K), Bayer AG (Germany), Sun Pharmaceuticals Industries Ltd. (India), Amneal Pharmaceuticals LLC. (U.K.), Alvogen (U.S)
Global Anti-Inflammatory Therapeutics Market Dynamics
- Rising Awareness of the Diseases
Increase in awareness of anti-inflammatory therapeutics and several government initiatives towards the treatment of inflammation with the help of non-steroidal anti-inflammatory drugs in Asia-Pacific and LAMEA are expected to boost the market growth. Thus, this boosts the market growth.
- Increasing Prevalence of Chronic Disorders
The rising prevalence of chronic disorders can lead to the growth in the market. Back in 2018, around 51.8% of U.S. adults had at least one chronic condition, and around 27.2% had multiple chronic conditions. The prevalence was highest among women, adults aged 65 or older, and those living in rural areas.
- Increasing Demand for Retail Pharmacies
The rise in the number of anti-inflammatory therapeutics being delivered through these retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increased Clinical Research
A lot of clinical activities are being performed that boost the market's growth. For instance, numerous clinical trials are currently on the way to improve this destructive inflammation. One of them is NLRP3 inflammasome, that targets multiple mechanisms which are associated with COVID-19 excessive inflammation. Thus, these factors positively impact the market growth during the global health crisis. Thus, it creates opportunity for the market growth.
- Impending Drug Approvals
There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global anti-inflammatory therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti-inflammatory therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Anti-Inflammatory Therapeutics Market
COVID-19 causes severe anti-inflammatory pneumonia, because COVID-19 can cause severe inflammation to patients diagnosed with it. As per the reports, cytokine storm is strongly responsible for death in such patients. Several consequences of severe inflammation and cytokine storms include acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes, which can lead to increased R&D of anti-inflammatory drugs for treating inflammation caused by COVID-19.
Global Anti-Inflammatory Therapeutics Market Scope
The global anti-inflammatory therapeutics market is segmented on the basis of drug class, indications, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Anti-Inflammatory Biologics
- Nonsteroidal Anti-Inflammatory (NSAIDs)
- Respiratory Diseases
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Anti-Inflammatory Therapeutics Market Regional Analysis/Insights
The global anti-inflammatory therapeutics market is analysed and market size insights and trends are provided by drug class, indications, distribution channel and end-user as referenced above.
The major countries covered in the global anti-inflammatory therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high prevalence of psoriasis and irritable bowel and large availability of treatment options.
Asia-Pacific dominates the market due to the presence of key generic pharmaceuticals companies in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anti-Inflammatory Therapeutics Market Share Analysis
The global anti-inflammatory therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anti-inflammatory therapeutics market.
Key players operating in the global anti-inflammatory therapeutics market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceuticals Industries Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.K.)
- Alvogen (U.S)